EYP-1901 for Wet Age-Related Macular Degeneration

EYP-1901 for Wet Age-Related Macular Degeneration
56%45%34%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 45.0%
EyePoint Pharmaceuticals, Inc. ($EYPT)
No stock close$13.79$12.60$11.41May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • EYPT $11.70May 19 • EYPT $11.82May 20 • EYPT $12.50May 21 • EYPT $12.78May 22 • EYPT $12.93May 26 • EYPT $13.35May 27 • EYPT $13.16May 28 • EYPT $13.50

Will this trial show a positive result on Average change in best corrected visual acuity (BCVA), Weeks 52 and 56?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle

Matched news2 items

All news
EYPT

EyePoint Announces First Patients Dosed in Both Global Phase 3 Clinical Trials of DURAVYU™ for the Treatment of Diabetic Macular Edema

– Active Phase 3 programs for DURAVYU in wet AMD and DME, the two largest multi-billion-dollar retinal disease markets – – Topline data for DURAVYU in DME anticipated in 2H 2027 – WATERTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing

Trial Start • Phase 3Matched macular, intravitreal, injection, aflibercept
EYPT

EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments

– Both pivotal Phase 3 trials for DURAVYU in wet AMD on track for data readout beginning in mid-2026 – – Patients dosed in both COMO and CAPRI Phase 3 clinical trials for DURAVYU in DME – – Michael Campbell appointed Chief Commercial Officer to lead launch strategy and readiness for DURAVYU

Trial Start • Phase 3Matched age-related, macular, degeneration, intravitreal, aflibercept